Ovarian Cancer – 95% benefit with Keytruda, Avastin and Cyclophosphamide
Ovarian, fallopian tube or primary peritoneal cancers - Keytruda, Avastin and Cyclophosphamide

Ovarian Cancer – 95% benefit with Keytruda, Avastin and Cyclophosphamide

Background Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable and effective therapies. About the…

Continue Reading Ovarian Cancer – 95% benefit with Keytruda, Avastin and Cyclophosphamide